Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX

Biochemical and Biophysical Research Communications

Volumn 316, Issue 4, 2004, Pages 1088-1093

  Ishii, Hideshi ^a   Mimori, Koshi ^b   Vecchione, Andrea ^c   Sutheesophon, Krittaya ^a   Fujiwara, Toshiyoshi ^d   Mori, Masaki ^b   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

E2F 1; FHIT; Tumor suppressor; WWOX

Indexed keywords

TRANSCRIPTION FACTOR E2F1;

ALLELE; ANIMAL CELL; APOPTOSIS; ARTICLE; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; DNA SEQUENCE; EMBRYO; FRAGILE HISTIDINE TRIAD GENE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WW DOMAIN CONTAINING OXIDOREDUCTASE GENE;

ACID ANHYDRIDE HYDROLASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMOSOME FRAGILE SITES; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OXIDOREDUCTASES; RECOMBINANT PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 1642416689     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.02.159     Document Type: Article

References (43)

1. Glover T.W., Berger C., Coyle J., Echo B. DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet. 67:1984;136-142.
2. Yunis J.J., Soreng A.L. Constitutive fragile sites and cancer. Science. 226:1984;1199-1204.
3. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60:2000;2140-2145.
4. Paige A.J., Taylor K.J., Taylor C., Hillier S.G., Farrington S., Scott D., Porteous D.J., Smyth J.F., Gabra H., Watson J.E. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. USA. 98:2001;11417-11422.
5. Mimori K., Druck T., Inoue H., Alder H., Berk L., Mori M., Huebner K., Croce C.M. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc. Natl. Acad. Sci. USA. 96:1999;7456-7461.
6. Huebner K., Croce C.M. FRA3B and other common fragile sites: the weakest link. Nat. Rev. Cancer. 1:2001;214-221.
7. Huebner K., Croce C.M. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br. J. Cancer. 88:2003;1501-1506.
8. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., Brenner A.J., Aldaz C.M. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 61:2001;8068-8073.
9. Ishii H., Ozawa K., Furukawa Y. Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J. Exp. Therapeu. Oncol. 3:2003;291-296.
10. Sozzi G., Sard L., De Gregorio L., Marchetti A., Musso K., Buttitta F., Tornielli S., Pellegrini S., Veronese M.L., Manenti G., Incarbone M., Chella A., Angeletti C.A., Pastorino U., Huebner K., Bevilaqua G., Pilotti S., Croce C.M., Pierotti M.A. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57:1997;2121-2123.
11. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., Tornielli S., Sard L., Huebner K., Pierotti M.A., Croce C.M., Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 58:1998;5032-5037.
12. Tseng J.E., Kemp B.L., Khuri F.R., Kurie J.M., Lee J.S., Zhou X., Liu D., Hong W.K., Mao L. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 59:1999;4798-4803.
13. Tomizawa Y., Nakajima T., Kohno T., Saito R., Yamaguchi N., Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res. 58:1998;5478-5483.
14. Nelson H.H., Wiencke J.K., Gunn L., Wain J.C., Christiani D.C., Kelsey K.T. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res. 58:1998;1804-1807.
15. Stein C.K., Glover T.W., Palmer J.L., Glisson B.S. Direct correlation between FRA3B expression and cigarette smoking. Gene. Chromosom. Cancer. 34:2002;333-340.
16. Pylkkanen L., Wolff H., Stjernvall T., Tuominen P., Sioris T., Karjalainen A., Anttila S., Husgafvel-Pursiainen K. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int. J. Oncol. 20:2002;285-290.
17. Mori M., Mimori K., Shiraishi T., Alder H., Inoue H., Tanaka Y., Sugimachi K., Huebner K., Croce C.M. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 60:2000;1177-1182.
18. Guo Z., Wu F., Asplund A., Hu X., Mazurenko N., Kisseljov F., Ponten J., Wilander E. Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. Mod. Pathol. 14:2001;54-61.
19. Arlt M.F., Miller D.E., Beer D.G., Glover T.W. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes Cancer. 33:2002;82-92.
20. Zhang S.Y., Liu S.C., Al-Saleem L.F., Holloran D., Babb J., Guo X., Klein-Szanto A.J. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol. Biomarker. Prev. 9:2000;395-401.
21. Susini T., Massi D., Paglierani M., Masciullo V., Scambia G., Giordano A., Amunni G., Massi G., Taddei G.L. Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. Hum. Pathol. 32:2001;360-367.
22. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
23. Wu X., Levine A.J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;3602-3606.
24. Furukawa Y., Nishimura N., Furukawa Y., Satoh M., Endo H., Iwase S., Yamada H., Matsuda M., Kano Y., Nakamura M. Apaf-1 is a mediator of E2F-1-induced apoptosis. J. Biol. Chem. 277:2002;39760-39768.
25. Milner A.E., Levens J.M., Gregory C.D. Flow cytometric methods of analyzing apoptotic cells. Methods Mol. Biol. 80:1998;347-354.
26. Fueyo J., Gomez-Manzano C., Yung W.K.A., Liu T.J., Alemany R., McDonnell T.J., Shi X., Rao J.S., Levin V.A., Kyritsis A.P. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat. Med. 4:1998;685-690.
27. Ishii H., Dumon K., Vecchione A., Trapasso F., Mimori K., Alder H., Mori M., Sozzi G., Baffa R., Huebner K., Croce C.M. Effect of adenoviral transduction of FHIT into esophageal cancer cells. Cancer Res. 61:2001;1578-1584.
28. Ausubel F.M., Brent R., Kingston R.E., Moor D.D., Seidman J.G., Smith J.A., Struhl K. Current protocols in molecular biology. 1989;Wiley-Interscience, New York.
29. Ishii H., Vecchione A., Furukawa Y., Sutheesophon K., Han S.-Y., Druck T., Kuroki T., Trapasso F., Nishimura M., Saito Y., Ozawa K., Croce C.M., Huebner K., Furukawa Y. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol. Cancer Res. 1:2003;940-947.
30. Kel A.E., Kel-Margoulis O.V., Farnham P.J., Bartley S.M., Wingender E., Zhang M.Q. Computer-assisted identification of cell cycle-related genes: new targets for E2F transcription factors. J. Mol. Biol. 309:2001;99-120.
31. Singh P., Wong S.H., Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J. 13:1994;3329-3338.
32. Johnson D.G., Cress W.D., Jakoi L., Nevins J.R. Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA. 91:1994;12823-12827.
33. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-548.
34. Yang H.L., Dong Y.B., Elliott M.J., Liu T.J., Atienza C. Jr., Stilwell A., McMasters K.M. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells. Clin. Cancer Res. 5:1999;2242-2250.
35. Dong Y.B., Yang H.L., Elliott M.J., Liu T.J., Stilwell A., Atienza C. Jr., McMasters K.M. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer. 86:1999;2021-2233.
36. Yang H.L., Dong Y.B., Elliott M.J., Liu T.J., McMasters K.M. Caspase activation and changes in Bcl-2 family member protein expression associated with E2F-1-mediated apoptosis in human esophageal cancer cells. Clin. Cancer Res. 6:2000;1579-1589.
37. Itoshima T., Fujiwara T., Waku T., Shao J., Kataoka M., Yarbrough W.G., Liu T.J., Roth J.A., Tanaka N., Kodama M. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin. Cancer Res. 6:2000;2851-2859.
38. Elliott M.J., Dong Y.B., Yang H., McMasters K.M. E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin. Cancer Res. 7:2001;3590-3597.
39. Ji L., Fang B., Yen N., Fong K., Minna J.D., Roth J.A. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59:1999;3333-3339.
40. Dumon K.R., Ishii H., Vecchione A., Trapasso F., Baldassarre G., Chakrani F., Druck T., Rosato E.F., Williams N.N., Baffa R., During M.J., Huebner K., Croce C.M. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 61:2001;4827-4836.
41. Trapasso F., Krakowiak A., Cesari R., Arkles J., Yendamuri S., Ishii H., Vecchione A., Kuroki T., Bieganowski P., Pace H.C., Huebner K., Croce C.M., Brenner C. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc. Natl. Acad. Sci. USA. 100:2003;1592-1597.
42. Chang N.S., Doherty J., Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J. Biol. Chem. 278:2003;9195-9202.
43. Chang N.S., Doherty J., Ensign A., Lewis J., Heath J., Schultz L., Chen S.T., Oppermann U. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem. Pharmacol. 66:2003;1347-1354.